Global Thematic Partners Lowered 58 Com (WUBA) Holding By $8.15 Million; Acadia Pharmaceuticals (ACAD) Sentiment Is 1.05

December 7, 2017 - By Linda Rogers

Global Thematic Partners Llc decreased 58 Com Inc (WUBA) stake by 25.13% reported in 2017Q2 SEC filing. Global Thematic Partners Llc sold 185,336 shares as 58 Com Inc (WUBA)’s stock rose 30.73%. The Global Thematic Partners Llc holds 552,220 shares with $24.36 million value, down from 737,556 last quarter. 58 Com Inc now has $10.34 billion valuation. The stock increased 3.37% or $2.3 during the last trading session, reaching $70.59. About 549,960 shares traded. Inc. (NYSE:WUBA) has declined 14.06% since December 7, 2016 and is downtrending. It has underperformed by 30.76% the S&P500.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company has market cap of $3.75 billion. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of ParkinsonÂ’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of AlzheimerÂ’s disease psychosis. It currently has negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.

Among 15 analysts covering (NYSE:WUBA), 7 have Buy rating, 3 Sell and 5 Hold. Therefore 47% are positive. had 24 analyst reports since August 21, 2015 according to SRatingsIntel. The stock of Inc. (NYSE:WUBA) earned “Outperform” rating by CLSA on Friday, May 26. The stock has “Buy” rating by Citigroup on Tuesday, August 8. HSBC downgraded the shares of WUBA in report on Tuesday, November 15 to “Hold” rating. The rating was initiated by Deutsche Bank on Wednesday, October 5 with “Buy”. The stock of Inc. (NYSE:WUBA) earned “Outperform” rating by Macquarie Research on Friday, July 8. The firm has “Buy” rating by TH Capital given on Wednesday, May 10. The company was downgraded on Friday, November 11 by Brean Capital. Credit Suisse downgraded the shares of WUBA in report on Friday, November 11 to “Neutral” rating. The firm has “Hold” rating given on Wednesday, December 14 by Deutsche Bank. The stock of Inc. (NYSE:WUBA) earned “Sell” rating by CLSA on Thursday, October 15.

Global Thematic Partners Llc increased Nike Inc (NYSE:NKE) stake by 1.00 million shares to 3.07M valued at $180.87 million in 2017Q2. It also upped Gilead Sciences Inc (NASDAQ:GILD) stake by 202,758 shares and now owns 1.05 million shares. Lazard Ltd (NYSE:LAZ) was raised too.

Baker Bros. Advisors Lp holds 6.3% of its portfolio in ACADIA Pharmaceuticals Inc. for 25.82 million shares. Sectoral Asset Management Inc owns 1.10 million shares or 3.35% of their US portfolio. Moreover, Harvey Capital Management Inc has 2.78% invested in the company for 232,150 shares. The California-based Venbio Select Advisor Llc has invested 2.16% in the stock. Palo Alto Investors Llc, a California-based fund reported 1.61 million shares.

The stock increased 1.68% or $0.5 during the last trading session, reaching $30.21. About 532,897 shares traded. ACADIA Pharmaceuticals Inc. (ACAD) has declined 15.19% since December 7, 2016 and is downtrending. It has underperformed by 31.89% the S&P500.

Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on February, 27. They expect $-0.59 earnings per share, up 9.23% or $0.06 from last year’s $-0.65 per share. After $-0.53 actual earnings per share reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 11.32% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By :